NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 100 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 4h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 100 is a fixed-dose combination tablet containing carbidopa (a DOPA decarboxylase inhibitor), levodopa (the active dopamine precursor), and entacapone (a COMT inhibitor) used to treat Parkinson's disease. It works by increasing dopamine availability in the brain while reducing peripheral metabolism of levodopa. This combination formulation provides symptom control for motor fluctuations in advanced Parkinson's disease patients.
$0.229MPart D
LOE ApproachingThis is a mature, declining-revenue product within a crowded family of STALEVO dosage strengths, signaling contraction rather than expansion of commercial teams.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STALEVO 100 offers limited career growth opportunities due to its LOE-approaching status and minimal linked job openings. Roles on this product are primarily focused on managing decline, converting patients to generics, and optimizing remaining revenue rather than growth-oriented activities.
Brand Manager
Worked on STALEVO 100 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.